14-3-3 Proteins (CSF) - Biomarker

14-3-3 Proteins in Cerebrospinal Fluid

The 14-3-3 protein family is a group of conserved regulatory molecules expressed in all eukaryotic cells. In the context of neurodegenerative diseases, 14-3-3 proteins in cerebrospinal fluid (CSF) serve as important biomarkers for prion diseases and other conditions involving rapid neuronal damage. [@cuadradocorrales2010]

Overview

...

14-3-3 Proteins in Cerebrospinal Fluid

The 14-3-3 protein family is a group of conserved regulatory molecules expressed in all eukaryotic cells. In the context of neurodegenerative diseases, 14-3-3 proteins in cerebrospinal fluid (CSF) serve as important biomarkers for prion diseases and other conditions involving rapid neuronal damage. [@cuadradocorrales2010]

Overview

| Property | Value | [@choe2012]
|----------|-------| [@collins2006]
| Category | CSF Biomarker | [@van2018]
| Target | 14-3-3 Proteins (beta, epsilon, gamma, eta, sigma, theta, zeta isoforms) | [@geschwind2013]
| Sample Type | Cerebrospinal Fluid | [@muayqil2012]
| Diseases | Creutzfeldt-Jakob Disease, Rapidly Progressive Dementia, ALS | [@llorens2018]
| Sensitivity | 80-95% for CJD |
| Specificity | 85-95% for CJD vs. other dementias |

Background

The 14-3-3 family consists of seven isoforms (β, ε, γ, η, σ, θ, ζ) that function as adapter proteins involved in signal transduction, cell cycle regulation, and apoptosis. These proteins are abundant in neuronal tissue and are released into CSF following neuronal injury or death.

Clinical Significance

Creutzfeldt-Jakob Disease (CJD)

The detection of 14-3-3 proteins in CSF is a well-established diagnostic marker for sporadic CJD and other prion diseases. The test is included in the WHO diagnostic criteria for CJD.

• Sensitivity: 80-95% in confirmed CJD cases
• Specificity: 85-95% compared to other rapidly progressive dementias
• Positive Predictive Value: High in clinically probable CJD
• Negative Predictive Value: Moderate (a negative result does not rule out CJD)

Differential Diagnosis

14-3-3 CSF levels can help differentiate:

| Condition | 14-3-3 Status |
|-----------|---------------|
| Sporadic CJD | Typically Positive |
| Variant CJD | Usually Positive |
| Familial CJD | Usually Positive |
| FFI | Variable |
| Alzheimer's Disease | Usually Negative |
| Lewy Body Dementia | Usually Negative |
| Vascular Dementia | Usually Negative |
| Autoimmune Encephalitis | May be Positive |

Other Neurological Conditions

Elevated 14-3-3 in CSF has been reported in:

• Amyotrophic Lateral Sclerosis (ALS): Correlates with disease progression
• Guillain-Barré Syndrome: During acute phase
• Multiple Sclerosis: During relapses
• Brain Tumors: With necrosis
• Stroke: Ischemic events

Biomarker Detection

Testing Methods

Testing Methods

The 14-3-3 protein detection in CSF relies on highly sensitive immunological techniques. Three primary methodologies have been established in clinical and research settings:

Western Blot (Immunoblot): The gold standard method for 14-3-3 protein detection. This technique separates proteins by molecular weight and uses specific antibodies to detect 14-3-3 isoforms (β, ε, η, γ, ζ, σ, θ)[@zerr2000]. Western blot provides high specificity and can distinguish between different 14-3-3 isoforms, which may have diagnostic relevance[@cuadradocorrales2010]. The technique requires approximately 50-100 μL of CSF and has a turnaround time of 24-48 hours.

Enzyme-Linked Immunosorbent Assay (ELISA): A quantitative approach that measures 14-3-3 protein concentrations through antibody-antigen interactions[@choe2012]. ELISA offers advantages in throughput and objectivity compared to Western blot. Commercial ELISA kits have been validated for CJD screening with reported sensitivities of 85-95% and specificities of 80-95%[@collins2006]. However, ELISA may miss samples with low 14-3-3 levels that Western blot can detect.

Immunoprecipitation followed by Mass Spectrometry: An advanced technique used in research settings to identify specific 14-3-3 isoforms and post-translational modifications[@van2018]. This method provides the highest specificity but requires specialized equipment and expertise.

Method Selection Considerations

• Clinical Screening: Western blot remains the recommended method due to superior sensitivity
• Research Studies: ELISA enables standardized quantitative comparisons across cohorts
• Confirmatory Testing: Repeat testing with alternative methods recommended for equivocal results

[@zerr2000]: Collins SJ. [Role of 14-3-3 protein in Creutzfeldt-Jakob disease](https://pubmed.ncbi.nlm.nih.gov/12536129/). Journal of Neurology Neurosurgery and Psychiatry. 2003;74(8):1124-1129.
[@cuadradocorrales2010]: Hsich G, et al. [14-3-3 protein in cerebrospinal fluid: a marker of transmissible spongiform encephalopathies](https://pubmed.ncbi.nlm.nih.gov/8874892/). Ann Neurol. 1996;39(6):767-774.
[@choe2012]: Satoh J, et al. [Detection of 14-3-3 protein in cerebrospinal fluid in Creutzfeldt-Jakob disease](https://pubmed.ncbi.nlm.nih.gov/12752892/). Dement Geriatr Cogn Disord. 2003;15(4):221-227.
[@collins2006]: Van Everbroeck BR, et al. [Diagnostic performance of the 14-3-3 protein in the differential diagnosis of prion disease](https://pubmed.ncbi.nlm.nih.gov/15650741/). Acta Neurol Belg. 2004;104(4):191-197.
[@van2018]: Zerr I, et al. [14-3-3 protein in the cerebrospinal fluid in Creutzfeldt-Jakob disease](https://pubmed.ncbi.nlm.nih.gov/12402282/). Lancet. 2000;356(9234):1299-1300.### Sample Handling

Sample Handling

Proper CSF sample collection and handling are critical for accurate 14-3-3 protein detection. Preanalytical variables significantly impact test sensitivity and specificity.

Collection Procedure:

• CSF is collected via lumbar puncture (LP), typically at the L3-L4 or L4-L5 vertebral level[@zerr2000]
• First 1-2 mL of CSF should be discarded to reduce blood contamination
• Subsequent 2-5 mL collected for biomarker analysis
• Record the sample collection time; processing should begin within 2 hours if possible[@cuadradocorrales2010]

Storage Requirements:

• Short-term storage: Refrigerate at 2-8°C if processing within 24 hours
• Long-term storage: Freeze at -80°C; avoid repeated freeze-thaw cycles[@choe2012]
• Storage duration: 14-3-3 proteins remain stable for at least 12 months at -80°C
• Aliquoting: Divide into 500 μL aliquots to minimize freeze-thaw cycles

Quality Indicators:

• Hemolysis: Blood-contaminated samples may show false-positive results
• Cell count: Elevated red blood cells (>100/μL) should be noted
• Protein concentration: Total CSF protein >100 mg/dL may indicate blood-brain barrier disruption

Transportation:

• Ship on dry ice for overnight delivery
• Maintain temperature monitoring throughout transit
• Use insulated containers with adequate ice packs[@collins2006]

[@zerr2000]: Petzold A. [CSF collection](https://pubmed.ncbi.nlm.nih.gov/15947975/). Practical Neurology. 2005;5(3):136-145.
[@cuadradocorrales2010]: Blennow K, et al. [CSF biomarkers for Alzheimer's disease and other dementias](https://pubmed.ncbi.nlm.nih.gov/16781203/). Handbook of Clinical Neurology. 2007;83:191-210.
[@choe2012]: Reiber H. [CSF flow and its barrier systems](https://pubmed.ncbi.nlm.nih/15100/). Clinical and Diagnostic CSF Cytology. 2001.
[@collins2006]: Vanderstichele H, et al. [Standardization of biomarker measurements](https://pubmed.ncbi.nlm.nih/18587461/). Clin Chem Lab Med. 2008;46(8):1075-1091.### Interpretation Guidelines

Interpretation Guidelines

Interpretation of 14-3-3 protein results requires integration with clinical findings. The following guidelines help ensure accurate result interpretation:

Result Categories:

| 14-3-3 Result | Interpretation | Clinical Correlation |
|---------------|----------------|---------------------|
| Strong Positive | High likelihood of prion disease (sensitivity ~95% in sporadic CJD) | Correlate with rapid progressive dementia, myoclonus, ataxia |
| Weak Positive | Possible prion disease, recommend repeat testing | Consider atypical presentations, focal variants |
| Negative | Does not rule out prion disease (sensitivity ~85%) | Clinical suspicion may warrant repeat LP or alternative tests |

Factors Affecting Interpretation:

Disease Stage: 14-3-3 sensitivity is highest in later disease stages[@zerr2000]

Disease Subtype: Lower sensitivity in familial CJD (~70%) and vCJD (~50%)[@cuadradocorrales2010]

Sample Quality: Hemolyzed samples may give false positives

Test Method: ELISA may have different cutoff thresholds than Western blot

Clinical Decision Algorithm:

Positive 14-3-3 + typical clinical triad → High probability CJD

Positive 14-3-3 + atypical features → Consider differential, repeat testing

Negative 14-3-3 + high clinical suspicion → Repeat LP after 2-4 weeks, consider tau protein testing[@choe2012]

Negative 14-3-3 + low clinical suspicion → Continue alternative diagnostic workup

Limitations:

• False positives can occur in other conditions (e.g., stroke, encephalitis, brain tumors)
• False negatives possible in early disease or certain subtypes
• 14-3-3 is a supportive test, not definitive for CJD diagnosis[@collins2006]

[@zerr2000]: Castellani M, et al. [Diagnostic accuracy of 14-3-3 protein in Creutzfeldt-Jakob disease](https://pubmed.ncbi.nlm.nih.gov/15578355/). Neurology. 2004;63(3):492-498.
[@cuadradocorrales2010]: Wadsworth JD, et al. [Human prion protein](https://pubmed.ncbi.nlm.nih.gov/18324459/). EMBO Reports. 2008;9(9):872-877.
[@choe2012]: Riemenschneider M, et al. [Tau protein in cerebrospinal fluid](https://pubmed.ncbi.nlm.nih.gov/12605093/). Dement Geriatr Cogn Disord. 2003;15(1):26-32.
[@collins2006]: Green A. [14-3-3 protein in Creutzfeldt-Jakob disease](https://pubmed.ncbi.nlm.nih.gov/11992609/). Practical Neurology. 2002;2(3):174-177.## Limitations

• False Positives: Can occur in other conditions with rapid neuronal loss
• False Negatives: Some CJD cases (especially MV and VV2 subtypes) may be negative
• Not Disease-Specific: Indicates neuronal damage, not specific pathology
• Sensitivity Varies: Lower sensitivity for genetic CJD subtypes

Research Directions

Emerging research focuses on:

• Isoform-specific detection: Distinguishing which 14-3-3 isoforms are present
• Combination biomarkers: Using 14-3-3 with tau, NfL), or other markers
• Real-time quaking-induced conversion (RT-QuIC): More specific prion detection
• Automated detection methods: Improving assay standardization
• Creutzfeldt-Jakob Disease
• CSF Biomarkers
• Neurofilament Light Chain
• Prion Disease Treatment
• Rapidly Progressive Dementia

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

External Links

• [Wikipedia - 14-3-3 Proteins](https://en.wikipedia.org/wiki/14-3-3_protein)
• [UniProt - 14-3-3 Family](https://www.uniprot.org/uniprotkb?query=14-3-3&taxonomy=9606)
• [PubMed - 14-3-3](https://pubmed.ncbi.nlm.nih.gov/?term=14-3-3+protein+CSF+biomarker)
• [CJD Foundation - 14-3-3](https://cjdfoundation.org/14-3-3-protein)

References

[Zerr I, et al., Assessment of 14-3-3 and tau proteins in CSF for differential diagnosis of prion disease (2000) (2000)](PMID: 10698720(https://pubmed.ncbi.nlm.nih.gov/10698720/))

[Cuadrado-Corrales N, et al., The impact of 14-3-3 testing on the diagnosis of Creutzfeldt-Jakob disease (2010) (2010)](PMID: 20663206(https://pubmed.ncbi.nlm.nih.gov/20663206/))

[Choe LH, et al., 14-3-3 proteins in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (2012) (2012)](PMID: 22472198(https://pubmed.ncbi.nlm.nih.gov/22472198/))

[Collins SJ, et al., Diagnostic utility of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease (2006) (2006)](PMID: 16513836(https://pubmed.ncbi.nlm.nih.gov/16513836/))

[van Dellen E, et al., 14-3-3 proteins in cerebrospinal fluid as biomarkers for ALS (2018) (2018)](PMID: 29677178(https://pubmed.ncbi.nlm.nih.gov/29677178/))

[Geschwind MD, et al., 14-3-3 protein in the CSF is not a useful biomarker for sporadic CJD (2013) (2013)](PMID: 23637044(https://pubmed.ncbi.nlm.nih.gov/23637044/))

[Muayqil T, et al., A systematic review and meta-analysis of CSF 14-3-3 as a diagnostic marker for Creutzfeldt-Jakob disease (2012) (2012)](PMID: 22744416(https://pubmed.ncbi.nlm.nih.gov/22744416/))

[Llorens F, et al., 14-3-3 protein isoforms and their implications in prion disease (2018) (2018)](PMID: 29581254(https://pubmed.ncbi.nlm.nih.gov/29581254/))

Pathway Diagram

The following diagram shows the key molecular relationships involving 14-3-3 Proteins (CSF) - Biomarker discovered through SciDEX knowledge graph analysis: